Opening of the inward rectifier potassium channel alleviates maladaptive tissue repair following myocardial infarction
Authors:
- 1 August 2016
- journal article
- research article
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 48 (8) , 687-695
Abstract
Activation of the inward rectifier potassium current (IK1) channel has been reported to be associated with suppression of ventricular arrhythmias. In this study, we tested the hypothesis that opening of the IK1 channel with zacopride (ZAC) was involved in the modulation of tissue repair after myocardial infarction. Sprague-Dawley rats were subject to coronary artery ligation and ZAC was administered intraperitoneally (15 µg/kg/day) for 28 days. Compared with the ischemia group, treatment with ZAC significantly reduced the ratio of heart/body weight and the cross-sectional area of cardiomyocytes, suggesting less cardiac hypertrophy. ZAC reduced the accumulation of collagen types I and III, accompanied with decrease of collagen area, which were associated with a reduction of collagen deposition in the fibrotic myocardium. Echocardiography showed improved cardiac function, evidenced by the reduced left ventricular end-diastolic dimension and left ventricular end-systolic dimension, and the increased ejection fraction and fractional shortening in ZAC-treated animals (all P < 0.05 vs. ischemia group). In coincidence with these changes, ZAC up-regulated the protein level of the IK1 channel and down-regulated the phosphorylation of mammalian target of rapamycin (mTOR) and 70-kDa ribosomal protein S6 (p70S6) kinase. Administration of chloroquine alone, an IK1 channel antagonist, had no effect on all the parameters measured, but significantly blocked the beneficial effects of ZAC on cardiac repair. In conclusion, opening of the IK1 channel with ZAC inhibits maladaptive tissue repair and improves cardiac function, potentially mediated by the inhibition of ischemia-activated mTOR-p70S6 signaling pathway via the IK1 channel. So the development of pharmacological agents specifically targeting the activation of the IK1 channel may protect the heart against myocardial ischemia-induced cardiac dysfunction.Keywords
Funding Information
- National Natural Science Foundation of China (81001294)
- Doctoral Startup Research Fund of Shanxi Medical University (03201405)
- Natural Science Foundation of Shanxi Province (2015021177)
This publication has 33 references indexed in Scilit:
- On the Risk Concerns of Zacopride, a Moderate IK1 Channel Agonist With Cardiac Protective ActionJournal of Cardiovascular Pharmacology, 2014
- Zacopride selectively activates the Kir2.1 channel via a PKA signaling pathway in rat cardiomyocytesScience China Life Sciences, 2013
- Short-term intermittent administration of CXCR4 antagonist AMD3100 facilitates myocardial repair in experimental myocardial infarctionActa Biochimica et Biophysica Sinica, 2013
- A Novel Discovery of IK1 Channel AgonistJournal of Cardiovascular Pharmacology, 2012
- Inwardly Rectifying Potassium Channels: Their Structure, Function, and Physiological RolesPhysiological Reviews, 2010
- Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial FibrillationPhysiological Reviews, 2007
- Pharmacology of cardiac potassium channelsCardiovascular Research, 2004
- Potassium channel down-regulation in heart failureCardiovascular Research, 1998
- Voltage‐gated and inwardly rectifying potassium channelsThe Journal of Physiology, 1997
- Effect of the serotonin-4 receptor agonist zacopride on aldosterone secretion from the human adrenal cortex: in vivo and in vitro studiesThe Journal of Clinical Endocrinology & Metabolism, 1993